Grand Pharmaceutical Group (FRA:MX6A) LT-Debt-to-Total-Asset : 0.05 (As of Dec. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Grand Pharmaceutical Group LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Grand Pharmaceutical Group's long-term debt to total assests ratio for the quarter that ended in Dec. 2024 was 0.05.

Grand Pharmaceutical Group's long-term debt to total assets ratio increased from Dec. 2023 (0.05) to Dec. 2024 (0.05). It may suggest that Grand Pharmaceutical Group is progressively becoming more dependent on debt to grow their business.

Grand Pharmaceutical Group LT-Debt-to-Total-Asset Historical Data

The historical data trend for Grand Pharmaceutical Group's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Grand Pharmaceutical Group LT-Debt-to-Total-Asset Chart

Grand Pharmaceutical Group Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.05

0.07

0.06

0.05

Grand Pharmaceutical Group Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.06	0.04	0.05	0.08	0.05

Grand Pharmaceutical Group LT-Debt-to-Total-Asset Calculation

Grand Pharmaceutical Group's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (A: Dec. 2024 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2024 )	/	Total Assets (A: Dec. 2024 )
	=	159.329	/	3070.286
	=	0.05

Grand Pharmaceutical Group's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (Q: Dec. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2024 )	/	Total Assets (Q: Dec. 2024 )
	=	159.329	/	3070.286
	=	0.05

Grand Pharmaceutical Group (FRA:MX6A) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Grand Pharmaceutical Group LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Grand Pharmaceutical Group's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Grand Pharmaceutical Group Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Grand Pharmaceutical Group Ltd (FRA:MX6A) » Definitions » LT-Debt-to-Total-Asset

Traded in Other Exchanges

00512:Hong Kong MX6A:Germany

Address

99 Queen's Road, Units 3302, 33rd Floor, The Center, Central, Hong Kong, HKG

Website

https://www.grandpharma.cn/en

Grand Pharmaceutical Group Ltd, formerly China Grand Pharmaceutical and Healthcare Holdings Ltd is a drug manufacturer. The company through its subsidiaries manufactures and sells pharmaceutical preparations and medical devices, biotechnology products, nutrition products, specialized pharmaceutical raw materials, and other products. Geographically, it derives a majority of revenue from the PRC and also has a presence in America; Europe; Asia other than the PRC and others.

Grand Pharmaceutical Group Headlines

No Headlines